Fulcrum Therapeutics Inc.

11.5100.00Vol 87.83K1Y Perf 15.11%
Apr 13th, 2021 16:00 DELAYED
BID11.51 ASK11.52
Open11.53 Previous Close11.51
Pre-Market- After-Market-
 - -  - -%
Target Price
18.71 
Analyst Rating
Strong Buy 1.13
Potential %
62.55 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     52.52
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap376.05M 
Earnings Rating
Price Range Ratio 52W %
29.26 
Earnings Date
12th May 2021

Today's Price Range

11.0811.55

52W Range

7.0122.39

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
1.05%
1 Month
-5.81%
3 Months
1.41%
6 Months
2.13%
1 Year
15.11%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FULC11.510.00000.00
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.73-0.6412.33
Q03 2020-0.66-0.70-6.06
Q02 2020-0.80-0.6617.50
Q01 2020-0.75-0.81-8.00
Q04 2019-0.84-0.7115.48
Q03 2019-0.62-0.97-56.45
Q02 2019-2.08-9.21-342.79
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th May 2021
Estimated EPS Next Report-0.70
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume87.83K
Shares Outstanding32.67M
Trades Count977
Dollar Volume911.93K
Avg. Volume141.25K
Avg. Weekly Volume92.46K
Avg. Monthly Volume114.05K
Avg. Quarterly Volume148.34K

Fulcrum Therapeutics Inc. (NASDAQ: FULC) stock closed at 11.51 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 87.83K shares and market capitalization of 376.05M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 73 people. Fulcrum Therapeutics Inc. CEO is Robert J. Gould.

The one-year performance of Fulcrum Therapeutics Inc. stock is 15.11%, while year-to-date (YTD) performance is -1.71%. FULC stock has a five-year performance of %. Its 52-week range is between 7.01 and 22.39, which gives FULC stock a 52-week price range ratio of 29.26%

Fulcrum Therapeutics Inc. currently has a PE ratio of -4.30, a price-to-book (PB) ratio of 4.09, a price-to-sale (PS) ratio of 48.04, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -59.01%, a ROC of -66.82% and a ROE of -77.68%. The company’s profit margin is -%, its EBITDA margin is -1 482.10%, and its revenue ttm is $8.07 Million , which makes it $0.25 revenue per share.

Of the last four earnings reports from Fulcrum Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.70 for the next earnings report. Fulcrum Therapeutics Inc.’s next earnings report date is 12th May 2021.

The consensus rating of Wall Street analysts for Fulcrum Therapeutics Inc. is Strong Buy (1.13), with a target price of $18.71, which is +62.55% compared to the current price. The earnings rating for Fulcrum Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Fulcrum Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Fulcrum Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.51, ATR14 : 1.25, CCI20 : -76.60, Chaikin Money Flow : -0.32, MACD : -0.25, Money Flow Index : 22.14, ROC : 0.00, RSI : 42.20, STOCH (14,3) : 55.75, STOCH RSI : 0.00, UO : 44.82, Williams %R : -44.25), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Fulcrum Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.13
Strong Buy
1.13
Strong Buy
1.13

Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability.

CEO: Robert J. Gould

Telephone: +1 617 651-8851

Address: 26 Landsdowne Street, Cambridge 02139, MA, US

Number of employees: 73

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

News

Stocktwits